Atara Biotherapeutics Stock Current Asset
| ATRA Stock | USD 12.12 0.65 5.67% |
Atara Biotherapeutics fundamentals help investors to digest information that contributes to Atara Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Atara Stock. The fundamental analysis module provides a way to measure Atara Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Atara Biotherapeutics stock.
The current year's Other Current Assets is expected to grow to about 8.6 M, whereas Non Current Assets Total are forecasted to decline to about 44.3 M. Atara | Current Asset |
Atara Biotherapeutics Company Current Asset Analysis
Atara Biotherapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Atara Biotherapeutics Current Asset | 324.6 M |
Most of Atara Biotherapeutics' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Atara Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Atara Current Asset Historical Pattern
Today, most investors in Atara Biotherapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Atara Biotherapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Atara Biotherapeutics current asset as a starting point in their analysis.
Atara Biotherapeutics Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Atara Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Atara Biotherapeutics has a Current Asset of 324.6 M. This is 84.92% lower than that of the Biotechnology sector and 69.4% lower than that of the Health Care industry. The current asset for all United States stocks is 96.52% higher than that of the company.
Atara Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Atara Biotherapeutics' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Atara Biotherapeutics could also be used in its relative valuation, which is a method of valuing Atara Biotherapeutics by comparing valuation metrics of similar companies.Atara Biotherapeutics is currently under evaluation in current asset category among its peers.
Atara Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Atara Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Atara Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Atara Fundamentals
| Return On Equity | -20.15 | ||||
| Return On Asset | -0.57 | ||||
| Profit Margin | (2.90) % | ||||
| Operating Margin | (0.62) % | ||||
| Current Valuation | 52.52 M | ||||
| Shares Outstanding | 5.76 M | ||||
| Shares Owned By Insiders | 22.15 % | ||||
| Shares Owned By Institutions | 50.82 % | ||||
| Number Of Shares Shorted | 636.28 K | ||||
| Price To Earning | (4.50) X | ||||
| Price To Book | 1.97 X | ||||
| Price To Sales | 1.12 X | ||||
| Revenue | 8.57 M | ||||
| Gross Profit | 63.57 M | ||||
| EBITDA | (266 M) | ||||
| Net Income | (276.13 M) | ||||
| Cash And Equivalents | 331.31 M | ||||
| Cash Per Share | 3.51 X | ||||
| Total Debt | 57.87 M | ||||
| Debt To Equity | 0.29 % | ||||
| Current Ratio | 5.28 X | ||||
| Book Value Per Share | (23.30) X | ||||
| Cash Flow From Operations | (192.98 M) | ||||
| Short Ratio | 7.11 X | ||||
| Earnings Per Share | (25.32) X | ||||
| Target Price | 14.75 | ||||
| Number Of Employees | 165 | ||||
| Beta | 0.5 | ||||
| Market Capitalization | 69.81 M | ||||
| Total Asset | 165.5 M | ||||
| Retained Earnings | (1.97 B) | ||||
| Working Capital | (40.36 M) | ||||
| Current Asset | 324.6 M | ||||
| Current Liabilities | 9.71 M | ||||
| Net Asset | 165.5 M |
About Atara Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Atara Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atara Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atara Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock:Check out Atara Biotherapeutics Piotroski F Score and Atara Biotherapeutics Altman Z Score analysis. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.32) | Revenue Per Share 12.263 | Quarterly Revenue Growth 28.927 | Return On Assets (0.57) | Return On Equity (20.15) |
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.